Sequana Medical Earnings inline, Revenue Beats In Q3
- Investing.com
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.
Metrics to compare | SEQUA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSEQUAPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.4x | −2.0x | −0.5x | |
PEG Ratio | −15.50 | −0.06 | 0.00 | |
Price/Book | −1.4x | 2.1x | 2.6x | |
Price / LTM Sales | 604.7x | 2.4x | 3.3x | |
Upside (Analyst Target) | 260.4% | 64.7% | 40.6% | |
Fair Value Upside | Unlock | 3.3% | 5.3% | Unlock |